StemRIM कमाई रिजल्ट पिछाडा, आय बराबर Q4 में
- Investing.com
तुलना करने के लिए मीट्रिक्स | 4599 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4599पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −6.0x | −7.9x | −0.4x | |
PEG अनुपात | −1.22 | −0.20 | 0.00 | |
क़ीमत/बुक | 1.9x | 3.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 22.3x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 295.5% | 142.7% | 54.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.5% | 7.2% | अनलॉक करें |
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.